JOP20190243A1 - علاج الربو بجسم مضاد لـ tslp - Google Patents

علاج الربو بجسم مضاد لـ tslp

Info

Publication number
JOP20190243A1
JOP20190243A1 JOP/2019/0243A JOP20190243A JOP20190243A1 JO P20190243 A1 JOP20190243 A1 JO P20190243A1 JO P20190243 A JOP20190243 A JO P20190243A JO P20190243 A1 JOP20190243 A1 JO P20190243A1
Authority
JO
Jordan
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
JOP/2019/0243A
Other languages
English (en)
Inventor
Jane R Parnes
Janet Griffiths
Original Assignee
Medimmune Llc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Amgen Inc filed Critical Medimmune Llc
Publication of JOP20190243A1 publication Critical patent/JOP20190243A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

يتعلق الكشف الحالي، على نحو عام، بطرق لمعالجة الربو، بما في ذلك الربو الحاد والربو الأيزونوفيلي، باستخدام جسم مضاد نوعي تجاه اللمفوبويتين السدوي السعتري (TSLP).
JOP/2019/0243A 2017-04-12 2017-06-16 علاج الربو بجسم مضاد لـ tslp JOP20190243A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01

Publications (1)

Publication Number Publication Date
JOP20190243A1 true JOP20190243A1 (ar) 2019-10-13

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0243A JOP20190243A1 (ar) 2017-04-12 2017-06-16 علاج الربو بجسم مضاد لـ tslp

Country Status (20)

Country Link
US (2) US10828365B2 (ar)
EP (1) EP3609917A1 (ar)
JP (2) JP7330896B2 (ar)
KR (1) KR20190140956A (ar)
CN (1) CN110573525A (ar)
AU (1) AU2018253118A1 (ar)
BR (1) BR112019021482A2 (ar)
CA (1) CA3059364A1 (ar)
CL (1) CL2019002897A1 (ar)
CO (1) CO2019011462A2 (ar)
IL (1) IL269791B (ar)
JO (1) JOP20190243A1 (ar)
MX (1) MX2019012158A (ar)
PE (1) PE20200484A1 (ar)
PH (1) PH12019502331A1 (ar)
SG (1) SG11201909322VA (ar)
TN (1) TN2019000289A1 (ar)
TW (1) TW201838652A (ar)
UY (1) UY37676A (ar)
WO (1) WO2018191479A1 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053914T2 (hu) * 2015-09-09 2021-07-28 Novartis Ag Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások
AU2020286889A1 (en) * 2019-06-04 2022-01-20 Jiangsu Hengrui Medicine Co., Ltd. Antibody capable of binding to thymic stromal lymphopoietin and use thereof
KR20220033504A (ko) * 2019-07-11 2022-03-16 타보텍 바이오테라퓨틱스 (홍콩) 리미티드 흉선 기질 림프포이에틴(tslp)-수용체 신호전달을 방해하는 제제
US20220289833A1 (en) * 2019-09-04 2022-09-15 Biosion Inc. Antibodies binding tslp and uses thereof
KR20220088752A (ko) * 2019-10-28 2022-06-28 메드임뮨 리미티드 흉선 기질 림포포이에틴 (tslp)-결합 항체들의 건조 분말 제형 및 이의 사용 방법
WO2021115240A1 (zh) * 2019-12-13 2021-06-17 四川科伦博泰生物医药股份有限公司 抗tslp抗体及其用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
UY39083A (es) * 2020-02-13 2021-08-31 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
AR121368A1 (es) * 2020-02-18 2022-06-01 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN116897053A (zh) * 2021-03-03 2023-10-17 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
JP2024516962A (ja) * 2021-04-19 2024-04-18 メドイミューン・リミテッド 安定性が改善された抗ＴＳＬＰ Ｆａｂ
WO2022226342A2 (en) 2021-04-23 2022-10-27 Amgen Inc. Modified anti-tslp antibodies
JP2024517418A (ja) 2021-04-23 2024-04-22 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体組成物及びその使用
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
CN102782149B (zh) 2009-11-04 2014-11-12 默沙东公司 经工程改造的抗-tslp抗体
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
MX2016005159A (es) * 2013-10-23 2016-07-05 Genentech Inc Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
US20170240631A1 (en) * 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN107428828A (zh) 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules

Also Published As

Publication number Publication date
JP2020516647A (ja) 2020-06-11
SG11201909322VA (en) 2019-11-28
UY37676A (es) 2018-10-31
EP3609917A1 (en) 2020-02-19
MX2019012158A (es) 2019-12-16
TN2019000289A1 (en) 2021-05-07
CO2019011462A2 (es) 2019-10-31
AU2018253118A1 (en) 2019-10-24
JP2023099233A (ja) 2023-07-11
IL269791B (en) 2022-07-01
TW201838652A (zh) 2018-11-01
PE20200484A1 (es) 2020-03-03
US10828365B2 (en) 2020-11-10
US20180296669A1 (en) 2018-10-18
CN110573525A (zh) 2019-12-13
KR20190140956A (ko) 2019-12-20
IL269791A (en) 2019-11-28
JP7330896B2 (ja) 2023-08-22
WO2018191479A1 (en) 2018-10-18
US20210052726A1 (en) 2021-02-25
PH12019502331A1 (en) 2020-09-28
BR112019021482A2 (pt) 2020-05-12
CL2019002897A1 (es) 2020-03-06
CA3059364A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MX2023002556A (es) Receptores quimericos y metodos de uso de los mismos.
PH12018502118A1 (en) Chimeric receptors to flt3 and methods of use thereof
MX2020006688A (es) Celulas presentadoras de antigenos artificiales y metodos de uso.
MX2019004834A (es) Anticuerpos de pd-1 y usos de estos.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
TN2018000076A1 (en) Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
BR122021000068A8 (pt) Composições e usos em métodos para estimular a eficácia de imunoterapia celular adotiva
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
CR20220189A (es) Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
MX2021008305A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MX2010007355A (es) Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion.